Rate My Professor Clement Loy

Professor Clement Loy (BA Pure Mathematics, MBBS, MMed(Clin Epi), FRACP Neurology, PhD in Clinical and molecular genetics of Frontotemporal Dementia, MBA, FRSN) serves as Head of School and Dean of Macquarie Medical School within the Faculty of Medicine, Health and Human Sciences at Macquarie University since 2023. A neurologist with subspecialty training in cognitive neurology from the National Hospital for Neurology and Neurosurgery, Queen Square, London, United Kingdom, and laboratory training at the Garvan Institute, Sydney, Australia, he has cared for families with Huntington Disease and genetic forms of dementia since 2000. He leads a quaternary referral service and research group for Huntington Disease at Westmead Hospital, Sydney, with a focus on clinical trials. Previously, he acted as Divisional Clinical Director and Medical Advisor at Westmead Hospital, taught extensively at the University of Sydney in the Master of Clinical Epidemiology program and MD evidence-based medicine courses, and led various teaching initiatives.

Professor Loy's academic interests lie in molecular genetics and clinical epidemiology, particularly Huntington Disease, genetic dementias, and clinical trials. He has published 119 papers and book chapters in esteemed journals including JAMA, The Lancet, New England Journal of Medicine, Cell, BMJ, Annals of Neurology, Lancet Neurology, and Brain. Key recent publications are 'What is the prevalence of sleep disturbances among people with Huntington disease and pre-manifest genetic expansion carriers? A systematic review and meta-analysis' (Sleep Medicine Reviews, 2026, with N.J. Sneddon et al.) and 'Effective housing and support models for people with Huntington's disease: a scoping review' (Journal of Huntington's Disease, 2025, with L. Cubis et al.). He has attracted more than $25 million in research funding and currently holds $6 million in grants and contracts as Chief Investigator A, along with one patent. Loy serves on the Pharmaceutical Benefits Advisory Committee, contributes to governance of the international Huntington Study Group, and is an elected councillor for the Hospitals Contribution Fund. His leadership and research significantly influence neurodegenerative disease management and advancement.